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ABSTRACT (190 words) 34 
Altered synaptic function is thought to play a role in many neurodegenerative diseases, but little is known 35 
about the underlying mechanisms for synaptic dysfunction.  The squid giant synapse (SGS) is a classical 36 
model for studying synaptic electrophysiology and ultrastructure, as well as molecular mechanisms of 37 
neurotransmission. Here, we conduct a multidisciplinary study of synaptic actions of misfolded human 38 
G85R-SOD1 causing familial Amyotrophic Lateral Sclerosis (fALS). G85R-SOD1, but not WT-SOD1, 39 
inhibited synaptic transmission, altered presynaptic ultrastructure, and reduced both the size of the 40 
Readily Releasable Pool (RRP) of synaptic vesicles and mobility from the Reserved Pool (RP) to the 41 
RRP. Unexpectedly, intermittent high frequency stimulation (iHFS) blocked inhibitory effects of G85R-42 
SOD1 on synaptic transmission, suggesting aberrant Ca2+ signaling may underlie G85R-SOD1 toxicity. 43 
Ratiometric Ca2+ imaging showed significantly increased presynaptic Ca2+ induced by G85R-SOD1 that 44 
preceded synaptic dysfunction. Chelating Ca2+ using EGTA prevented synaptic inhibition by G85R-45 
SOD1, confirming the role of aberrant Ca2+ in mediating G85R-SOD1 toxicity. These results extended 46 
earlier findings in mammalian motor neurons and advanced our understanding by providing possible 47 
molecular mechanisms and therapeutic targets for synaptic dysfunctions in ALS as well as a unique 48 
model for further studies.  49 
 50 
SIGNIFICANCE STATEMENT 51 
The squid giant synapse presents one of the few mature nervous systems in situ that mimics mammalian 52 
neuromuscular junctions, while allowing precise experimental manipulations and live measurement with 53 
superior spatial and temporal resolution. Applying these unique features to studying the molecular 54 
mechanisms of ALS, a devastating adult-onset neurodegenerative disease without cure, offers clues to 55 
understand the pathogenesis of the disease. Our results demonstrating synaptic dysfunction caused by 56 
ALS-associated mutant SOD1 protein and its underlying molecular pathways may suggest a novel 57 
  3 
approach to an effective therapeutic intervention as well as identify biomarkers for early diagnosis. 58 
Furthermore, the altered synaptic vesicle behavior and Ca2+ dynamics revealed through the perturbation 59 
of neurotransmission by ALS extends our understanding of fundamental synaptic physiology at both 60 
molecular and cellular levels.  61 
 62 
INTRODUCTION 63 
ALS is a fatal adult-onset neuromuscular disease with dysfunction and loss in both upper and lower 64 
motor neurons, resulting in progressive muscle weakness and atrophy, eventual paralysis, and death 65 
usually within 3-5 years after initial diagnosis. Inherited forms of ALS represent roughly 10% of cases, 66 
with similar clinical symptoms to sporadic ALS patients. Unfortunately, there is still no effective cure for 67 
ALS. To enable therapeutic intervention at an early stage of the disease, the mechanisms underlying ALS 68 
and presymptomatic biomarkers for early diagnosis must be identified. 69 
Mutations in Cu/Zn superoxide dismutase (SOD1) are responsible for ~25% of familial ALS cases, 70 
but SOD1 is expressed in many cell types where it removes superoxide radicals and is a component of 71 
redox signaling pathways. ALS-associated mutations induce a conformational change within SOD1 due 72 
to protein misfolding (Bruijn et al. 1998) and aberrant interactions with other proteins (Pasinelli et al. 73 
2004; Urushitani et al. 2006).  Genetic knock-out of SOD1 does not produce motor deficits seen in ALS, 74 
indicating that SOD1 mutations confer a toxic gain-of-function (Taylor, Brown, and Cleveland 2016; 75 
Ghasemi and Brown 2018; Bunton-Stasyshyn et al. 2015). A glycine-to-arginine substitution at residue 85 76 
(G85R) is one highly studied ALS-associated mutation: G85R-SOD1 is incapable of dimerizing normally 77 
and instead misfolds into soluble monomers or oligomers, as well as insoluble aggregates that are toxic to 78 
motor neurons (Wang, Farr, Zeiss, et al. 2009; Wang, Farr, Hall, et al. 2009).  79 
To characterize G85R-SOD1 toxicity, various forms of misfolded G85R-SOD1-YFP were perfused 80 
into isolated axoplasm from squid giant axons (Song et al. 2013), and both soluble monomers and 81 
oligomers inhibited axonal transport from cell body to synapse through aberrant activation of signaling 82 
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pathways (Song et al. 2013). Although G85R-SOD1 inhibition of anterograde transport of synaptic 83 
components could lead to synaptic dysfunction, questions remained as to whether G85R-SOD1 has a 84 
direct effect on synaptic transmission. Impairment of neuromuscular junctions is detected early in patients 85 
and animal models (Moloney, de Winter, and Verhaagen 2014), consistent with a “dying-back” 86 
neuropathy where synaptic dysfunction and loss is a primary pathology eventually leading to neuronal 87 
death. Decreased synaptic vesicle numbers and reduced presynaptic proteins in presynaptic terminals of 88 
several ALS animal models further suggest a presynaptic effect (Wang, Farr, Hall, et al. 2009). These 89 
changes are seen before motor deficits are detectable, suggesting that synapses could be a primary target 90 
of G85R-SOD1 (Sakowski et al. 2012; Hegedus, Putman, and Gordon 2007; Frey et al. 2000; Fischer et 91 
al. 2004).  92 
Synaptic transmission is altered in ALS mouse models and iPSC-derived motor neurons,  raising key 93 
questions: How do ALS-associated proteins alter synaptic functions?  Can synaptic function be restored? 94 
Unfortunately, the complexity of mouse motor systems, chronic nature of disease pathology, small size of 95 
presynaptic domains, and difficulty of targeting synapses limit utility of mouse and cell culture models in 96 
addressing questions about presynaptic mechanisms.  97 
The squid giant synapse, which mimics neuromuscular junctions with similar ion channel 98 
compositions and neurotransmission machinery (Katz and Miledi 1977, 1967), was used to evaluate pre- 99 
and post-synaptic actions of G85R-SOD1. The large size of squid giant presynaptic terminals permits 100 
experimental manipulations such as protein microinjection, direct electrophysiological measurements of 101 
transmission, current and voltage clamping, and Ca2+ imaging, facilitating detailed studies of presynaptic 102 
molecular mechanisms (Bloedel et al. 1966; Fukuda et al. 1995; Lin et al. 1990; Llinas et al. 1985; Llinas, 103 
Steinberg, and Walton 1980; Llinas, Sugimori, and Silver 1994; Sugimori et al. 1998; Augustine 1990; 104 
Augustine and Charlton 1986; Augustine, Charlton, and Horn 1988; Augustine et al. 2006). The squid 105 
synapse is particularly suitable for studying ALS, because it is (1) fast-transmitting with high release 106 
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capacity, similar to synapses affected in ALS; and (2) enriched in ion channels (e.g. Ca2+), 107 
neurotransmitters (e.g. glutamate) and receptors (e.g. AMPAR) implicated in ALS pathology.  108 
Here, we microinjected G85R-SOD1 in presynaptic terminals, recorded both pre- and post-synaptic 109 
membrane potentials with and without high-frequency-stimulations (HFS), performed live ratiometric 110 
Ca2+ imaging, and examined synaptic vesicle morphology/distribution by Electron Microscopy (EM). 111 
Correlated functional and structural studies demonstrated the acute synaptic inhibition by G85R-SOD1 as 112 
evidenced by diminished postsynaptic potentials (PSP), decreased synaptic vesicle number at active 113 
zones, and reduced synaptic mobilization from reserved (RP) to readily releasable pool (RRP) within 114 
30min after G85R-SOD1 injection. Unexpectedly, while continuous trains of high frequency stimulation 115 
(HFS) depleted synaptic vesicle availability and enhanced synaptic inhibition by G85R-SOD1, 116 
intermittent HFS (iHFS) applied every 30min before and during G85R-SOD1 infusion kept synapses 117 
firing normally for 7h. Given the effects of HFS on presynaptic Ca2+, we tested for aberrant Ca2+ signaling 118 
by ratiometric Ca2+ imaging with presynaptic Fura-2. Ca2+ increased throughout terminals including in 119 
“palm” regions before presynaptic axons branch, which lack plasmalemmal Ca2+ channels. Reducing 120 
intracellular Ca2+ by EGTA rescued synaptic function and restored normal structure in the presence of 121 
G85R-SOD1 as did iHFS. These results are consistent with and extend findings in mammalian nervous 122 
systems where neurons with lower Ca2+ buffering capacity are selectively affected in ALS and these 123 
neurons showed Ca2+ imbalances presymptomatically (Grosskreutz, Van Den Bosch, and Keller 2010). 124 
Understanding sources of increased Ca2+ and molecular mechanisms underlying Ca2+ activation as well as 125 
how iHFS rescues synaptic function will provide unique insights into synaptic dynamics and a possible 126 
molecular basis for synaptic pathology in human ALS patients.  127 
 128 
MATERIALS AND METHODS 129 
Proteins and Reagents 130 
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G85R-SOD1-His, WT-SOD1-His, G85R-SOD1-His-YFP, WT-SOD1-His-YFP were produced in 131 
E.Coli BL21/DE3 cells under pET vectors, and purified on Talon resin first and then by chromatography 132 
on MonoQ 10/10, in the Horwich Laboratory as described previously (Song et al. 2013). All chemicals 133 
used were American Chemical Society quality or better, from Sigma and Molecular Probes (now Fisher-134 
Scientific). For microinjection, proteins and reagents were dissolved in 200mM KCl, 100mM Taurine, 135 
250mM K-isethionate, 50mM K-Hepes, pH 7.4). Tetramethylrhodamine-dextran (3 kDa, Molecular 136 
Probes) was used for co-injection with non-fluorescent reagents to visualize and monitor the injection.  137 
Squid Giant Synapse preparation and electrophysiology setup 138 
The giant squid synapse is formed between the terminal finger of 2nd order axons of the pre-nerve and the 139 
3rd order axon of the last stellate nerve, which is the giant axon used for axonal transport studies as well as 140 
for classical voltage-clamp studies of ion channels (Young and Keynes 2005). Following a standard 141 
protocol (Augustine 1990; Augustine and Charlton 1986; Augustine, Charlton, and Horn 1988; Augustine 142 
et al. 2006; Llinas et al. 1985; Llinas, Steinberg, and Walton 1980, 1981; Llinas, Sugimori, and Silver 143 
1994; Smith et al. 1993), stellate ganglia of small female Loligo pealeii (RRID: SCR_002864, Marine 144 
Biological Laboratory, Woods Hole, Massachusetts) were removed from the mantle carefully and rapidly 145 
under running seawater, tied off at each end of the presynaptic and postsynaptic axons, isolated from the 146 
sheath and connective tissues, pinned with fine cactus needles to a thin-layer of Sylgard on the bottom of 147 
a 35mm Petri dish chamber, superfused continuously with oxygenated squid saline (455mM NaCl, 54mM 148 
MgCl2, 11mM CaCl2, 10mM KCl, 3mM NaHCO3, and 10mM Hepes, pH 7.2) at 10-15oC.  149 
The most distal digit of the presynaptic axons and the most medial fiber, also known as the giant 150 
axon, form the giant synapse (Figure 1A). One microelectrode for injecting was inserted in the 151 
presynaptic axon to inject current at 0.033 Hz for basal stimulation and at 50 Hz for HFS (each pulse is 152 
2μA for 2ms for basal stimulation and 2μA for 1ms for HFS), near the “palm” where the 2nd order axon 153 
enters the ganglion to branch and form multiple synapses with postsynaptic axons.  At the terminal of the 154 
most medial branch, a 2nd microelectrode was inserted to presynaptically inject proteins and reagents of 155 
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interest as well as recording the presynaptic membrane potentials. Finally, at the postsynaptic terminal of 156 
the giant synapse, a 3rd microelectrode was inserted near the medial presynaptic digit to record the 157 
postsynaptic membrane potentials. Electrodes 1 and 3 were filled with 3M KCl while the 2nd 158 
microelectrode, through which 50μM SOD1 proteins or reagents of interest were injected in 100mM KCl 159 
(Smith et al. 1993) at 0.1 Hz (each injection was 50 psi for 250 ms). The injection efficiency of SOD1 160 
proteins was monitored by a fluorescence microscope. All synapses were injected with the same pressure 161 
for the same amount of time during data acquisition, and the final mean fluorescence intensities in the 162 
presynaptic terminals were measured and compared between samples to ensure comparable levels of 163 
infused proteins. 164 
 165 
Electrophysiology data acquisition and analysis 166 
Both presynaptic and postsynaptic potentials (PSP) were recorded using sharp microelectrodes with 167 
an Axoclamp-2A amplifier (Axon Instrument, Foster City, CA) and data analyzed using Labview 168 
(National Instruments) software (Yulong Li). Raw waveforms were used to calculate PSP slope using the 169 
same parameters for all experiments. For data acquired under HFS, PSP slopes were analyzed, integrated, 170 
plotted, and fitted linearly using the last 50 time points to derive the vesicle mobilization rate (slope of the 171 
linear fit) and the readily releasable pool (RRP) size (intersection with the Y axis). 172 
Ratiometric Ca2+ imaging 173 
1mM Fura-2 (pentapotassium salt, ThermoFisher F1200, CHEBI:52081), a Ca2+ indicator, was 174 
dissolved in 100mM KCl and infused into the presynaptic terminal by electrophoresis (100 nA current) 175 
through the 1st presynaptic electrode inserted in the “palm”. Fura-2 infusion continued for 10min and the 176 
synapse was allowed to equilibrate for 30 min before presynaptic injection of SOD1 proteins through the 177 
2nd microelectrode to ensure Fura-2 was diffused evenly throughout the whole presynaptic terminal at 178 
roughly 100μM. Ratiometric live Ca2+ imaging was performed every 30 seconds with ratiometric images 179 
taken at Ex360 nm and Ex390 nm assisted by an ultra-high-speed wavelength switching Lambda DG-4/5 180 
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xenon arc lamp system. Ratios at various locations (A) were calculated as (fluorescent 181 
intensity360nm)/(fluorescent intensity390nm) as a measure of intracellular Ca2+ concentration (Smith et al. 182 
1993).  In vitro calibration was performed by mixing squid axoplasm with equal volumes of buffer 183 
containing 5μM Fura-2, 400mM KCl, and 40mM Na-HEPES (pH 7.2). 3 doses of CaCl2 were set by 184 
adding 20mM EGTA (low Ca2+, <10-8 M), or 20mM EGTA + 13.3 mM CaCl2 (intermediate Ca2+, ~6.7 x 185 
10-7 M), or 20mM CaCl2 (high Ca2+). Various ratios under each condition were measured using the same 186 
optics and the background noise was subtracted. The dose response curve was obtained to allow the 187 
determination of Kd’ and the two ratios. Rmax was defined as the ratio value at saturating Ca2+ level, and 188 
Rmin was defined as the ratio value at the minimal Ca2+ concentration. 189 
Electron Microscopy (EM) 190 
After recordings, synapses were fixed in 4% glutaraldehyde and 2% paraformaldehyde in 0.1M 191 
cacodylate buffer for 12 hours at 4oC, then washed in 0.1M cacodylate buffer 3 times and post-fixed in 192 
1% Osmium Tetroxide for 2 hours at 4oC, followed by blocking impregnation with 2% uranyl acetate in 193 
0.1M sodium acetate, pH 5.0 for 24 hours. After washing, dehydration was performed in ethanol with 194 
increasing concentration: 50% for 10min, 75% for 10min, 80% for 10min, 85% for 10min, 95% for 195 
10min, 100% for 5min twice, followed by propylene oxide for 5min three times. Resin and propylene (1:1 196 
for 24 hours, 2:1 overnight, and 3:1 for 2-4 hours, and finally 100% resin overnight) infiltration was 197 
carried out before embedding in silicone molds in the oven at 62 oC for 72 hours. Sectioning and imaging 198 
were performed following standard EM protocols (Moreno et al. 2009; Augustine et al. 2006). Vesicle 199 
density at the active zones was determined as the number of vesicles per μm2. Distance between vesicles 200 
and active zones was measured and plotted as described previously (Morgan et al. 1999). All EM samples 201 
were numbered, processed, and analyzed under blinded conditions till the last step when data had to be 202 
pooled.  203 
Statistical Information. 204 
  9 
All experiments were repeated at least five times. The data were analyzed by one-way ANOVA 205 
followed by the Tukey post-hoc test (or nonparametric multiple t-tests, without assuming consistent SD) 206 
and plotted in Prism 7 (GraphPad software). Quantitative data were plotted as mean r SEM. P values 207 
were calculated and four statistical thresholds were marked: P<0.00001, P<0.0001, P<0.001 and P<0.005 208 
(P<0.05 indicated statistical significance). For EM analysis, nested one-way ANOVA was performed to 209 
compare WT and G85R infused synapses (102 synapses across 3 synapses for each group). 210 
 211 
RESULTS 212 
G85R-SOD1-YFP but not WT-SOD1-YFP inhibits synaptic transmission 213 
To assess whether the mutant SOD1 is directly toxic to the synapse, as opposed to indirectly 214 
affecting it, e.g. by blocking axonal anterograde vesicular trafficking (Song et al. 2013), G85R-SOD1-215 
YFP (n = 8) or WT-SOD1-YFP control (n = 5) was microinjected in the presynaptic terminal site 216 
(Fig.1A) through the micropipette extending in from lower right; note that black color indicates the extent 217 
of YFP fluorescence after 40 min of infusion.  Another microelectrode was used to pass current pulses for 218 
basal stimulation (2 μA x 2 msec, every 33 sec) (Fig.1A, micropipette extending in from lower left) to 219 
evoke single action potentials, detected by intracellular voltage recording simultaneously from both pre- 220 
and post-synaptic sites (Fig 1A for sites of recording and Fig.1B middle and bottom traces). This protocol 221 
is referred to hereafter as “basal stimulation”.  Measurement of voltage changes at both pre- and 222 
postsynaptic sites allows for assessment of the efficiency of synaptic transmission. Strikingly, after 40 223 
min of G85R-SOD1-YFP infusion, the postsynaptic action potential was no longer detected, with only a 224 
subthreshold PSP observable (Fig.1B, Vpost).  By comparison, there was no change in the postsynaptic 225 
potential with a WT-SOD1-YFP infusion (Fig.1B Control) or with fluorescent dextran alone (Fig.1-1). A 226 
time course study of WT-SOD1-YFP and G85R-SOD1-YFP was carried out to observe the kinetic 227 
behavior of EPSPs from basal stimulation during the respective infusions (Fig.1C; note that points are 228 
shown only for every 10th pulse, i.e. at 5 min intervals).  With infusion of the mutant protein, the EPSP 229 
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slope began to reduce by ~10 min, and was completely lost by ~60-70 min. By contrast, no effect on 230 
EPSP was observed with WT-SOD1-YFP infusion for greater than 100 min (Fig.1C).  Thus, in contrast 231 
with the absence of an observable effect of WT-SOD1 infusion upon postsynaptic EPSP, injection of 232 
monomeric G85R-SOD1-YFP produced a substantial time-dependent inhibition of synaptic transmission. 233 
To rule out the possibility that synaptic defects were caused by physical damage induced by 234 
electrode impalement and microinjection, injection was stopped when postsynaptic action potentials were 235 
abolished. This allowed the diffusion of G85R-SOD1-YFP away from the synaptic terminal through the 236 
presynaptic axon. The EPSP slope started to increase 90min later as the presynaptic fluorescent intensity 237 
of G85R-SOD1-YFP significantly decreased and EPSPs were fully restored in about 2.5 hours after most 238 
mutant SOD1 had diffused out of the terminal (Fig.1-2). Normal synaptic transmission continued for 239 
more than 1 hour until a second injection of G85R-SOD1-YFP significantly inhibited synaptic 240 
transmission in the same fashion as the first injection. These results suggested that G85R-SOD1-YFP 241 
inhibits synaptic transmission at least in part by directly affecting neurotransmitter release from the 242 
synaptic terminal and this effect was reversible upon the removal of G85R-SOD1-YFP from the synaptic 243 
terminal.    244 
G85R-SOD1-YFP impairs synaptic vesicle availability at the active zone 245 
To examine whether G85R-SOD1-YFP inhibited synaptic transmission by affecting synaptic vesicle 246 
pool dynamics, we microinjected G85R-SOD1YFP or WT-SOD1-YFP for 15 min and then applied trains 247 
of high frequency stimulation (HFS) presynaptically (50 Hz for 5 sec, with 5 sec intervals between trains) 248 
and measured postsynaptic depression of EPSPs, which are proportional to the underlying EPSCs and are 249 
uncontaminated by action potentials, to determine the size of the readily releasable pool (RRP) and the 250 
rate of vesicle mobilization from the reserved pool (RP).  EPSP slopes during both the 1st train of a series 251 
trains of HFS (Fig.2A) and the 6th train (Fig.2-1) were compared in WT and G85R synapses.  For 252 
controls, there was a two-phase diminution of EPSP slope across the 250 spikes, whereas with G85R 253 
synapses the first phase was barely detectable during the 6th train of HFS and was significantly inhibited 254 
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during the 1st train. The first phase is generally associated with utilization of the RRP, which appears to be 255 
smaller with the mutant, whereas the second phase is generally associated with utilization of the RP, 256 
which appears to be present in both with significant reduction by G85R-SOD1-YFP.  To further measure 257 
these pools, the EPSP slope values were continuously integrated across one train of the same synapse 258 
prior to infusion and one train after 30 min of WT- or G85R-SOD1-YFP infusion.  The EPSPs of each 259 
condition were integrated and averaged to generate traces (Fig.2B). Notably, the WT-SOD1 trace 260 
resembled that of the preinfusion trace (not shown), indicating that WT-SOD1 has little effect on synaptic 261 
vesicle availability and mobilization, whereas G85R-SOD1 trace exhibited integrated values that were 262 
substantially lower than those of WT-SOD1.  The relative size of the RRP was determined for each 263 
condition by intersection of slope with the Y axis, and the mobilization rate from the RP was directly 264 
determined from the slopes (dotted lines; linear fit of the integrated EPSP slopes from the last 50 time 265 
points).  The values and statistics for independent experiments are shown (n=11 for WT and n=6 for 266 
G85R, Fig.2C).  G85R-SOD1-YFP drastically reduced both the RRP size and the vesicle mobilization 267 
rate from RP to RRP as compared with WT-SOD1-YFP.   Therefore, reduced RRP size and slower RP 268 
mobilization rate, could lead to the loss of synaptic transmission.  269 
Electron microscopy (EM) of WT-SOD1-YFP and G85R-SOD1-YFP-infused synapses 270 
To visualize the synaptic vesicles directly, we carried out EM analyses of synapses infused for 40 271 
min under basal stimulation with the respective proteins (n = 3 for each group).  The WT-SOD1-YFP-272 
infused synapses exhibited normal morphology with abundant packing of synaptic vesicles against the 273 
presynaptic membrane, comparable to published EM data (Augustine et al. 2006) of normal squid giant 274 
synapse (Fig.3A, red * indicates an active zone, AZ), whereas the G85R-SOD1-YFP-infused synapses 275 
reproducibly exhibited synaptic vesicles that did not abut the membrane at active zones, lying in a zone 276 
distant from it (Fig.3B).  The vesicles present in this zone also appeared generally larger, less compact in 277 
morphology and reduced in number relative to WT-SOD1 synapses.  We also consistently observed 278 
additional structures, e.g. in this image, what appears to be a pre-autophagosome (labeled by blue #) and 279 
two adjoining prelysosomes (labeled by purple ^).  By contrast we did not observe such structures in WT-280 
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SOD1-infused presynaptic active zones.  Notably, many of the pre-autophagosomes appeared to contain 281 
vesicles.  This potentially reflects a local mechanism to remove G85R-SOD1-YFP-affected synaptic 282 
vesicles in the RRP and a subpopulation of vesicles in the RP, whereas, interestingly, the most remote RP 283 
pools appear to be spared, suggesting a potential source for synaptic vesicle supply, which may help 284 
restoring synaptic function if released upon proper stimulations. More detailed characterization of 285 
affected vesicles was carried out by counting the number of electron lucent vesicles, clathrin coated 286 
vesicles, and large electron lucent vesicles per active zone as described previously (Morgan et al. 1999) 287 
(Fig.3C-F). Nested ANOVA analyses suggested that while clathrin coated vesicles did not seem to be 288 
affected by G85R-SOD1, the total number of available synaptic vesicles was dramatically reduced. A 289 
cumulative measurement of AZs (102 across 3 biological repeats per group) infused with WT-SOD1 or 290 
G85R-SOD1 (binned by 50μm in distance) showed that such reductions seem to be evenly distributed in 291 
the RRP regardless of the distance from the membrane (Fig.3G-I). Due to the limited number of vesicles 292 
further away from the AZs (>675μm) in both groups, the increase in the relative vesicle distribution in 293 
that vicinity didn’t seem to be statistically different between the G85R-SOD1-infused synapses and the 294 
WT-SOD1-infused synapses. This is further confirmed by the cumulative vesicle distribution curves 295 
(without binning) in WT and G85R-SOD1 synapses (Fig.3I). 296 
Prevention of G85R-SOD1-YFP-associated synaptic deficits by intermittent HFS (iHFS) 297 
Unexpectedly, when a single train of high frequency stimulation (HFS; 50 Hz for 5 sec) was applied 298 
presynaptically every 30 min, G85R-SOD1-YFP-infused synapses, otherwise receiving continuous basal 299 
stimulation, maintained constant EPSPs for over 8 hr (Fig.4A-C).  This contrasts with the finding (Fig.1) 300 
that in the setting of G85R-SOD1-YFP infusion, continuous basal stimulation leads to steady decline and 301 
then complete loss of EPSPs within 40-60 min.  This also contrasts with the finding (Fig.2) that 302 
continuous HFS trains with 5sec intervals also inhibited synaptic transmission by depletion of the RRP.  303 
Correlating with maintenance of healthy physiology, synaptic vesicle dynamics appeared to be normal, as 304 
demonstrated by presence of the first phase of EPSP slope during a single 50 Hz train, reflecting presence 305 
of an RRP resembling wild-type (Fig.4D).  Additionally, the integrated EPSP slope averaged across 306 
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multiple 50 Hz trains now resembled that of WT-SOD1-YFP synapses (n = 6 for each, Fig.4E).  Finally, 307 
in EM analyses (Fig.4F), consistent with presence of a normal RRP, vesicles were observed abutting the 308 
active zone after iHFS was applied to a synapse infused with G85R-SOD1-YFP for 6 hours These results 309 
indicate that iHFS is able to preserve the RRP in the face of G85R-SOD1-YFP infusion. Interestingly, in 310 
G85R-SOD1-injected synapses (3 out of 5) with dramatic decreases in the slope of the PSP but remaining 311 
>50, application of one HFS train restored EPSP slope and the RRP size, without rescuing vesicle 312 
mobilization rate (Fig.4-1). However, in the other 2 synapses where PSP slopes dropped to below 50, 313 
adding one HFS further reduced them to almost 0. This suggests that to achieve the rescuing effects, the 314 
timing of the HFS application with regard to existing synaptic strength is important. However, the 315 
underlying molecular mechanism of this rescuing effect is unclear and requires further study. Altogether, 316 
the intermittent stimulation reverses toxicity of the misfolded protein by restoring synaptic vesicle 317 
availability at the active zone.    318 
G85R-SOD1 induces Ca2+ increase in the presynaptic terminal 319 
Intrigued by the rescuing effect of iHFS in G85R-SOD1-infused synapses, we examined potential 320 
mechanisms. Since iHFS is known to alter Ca2+ dynamics, we wondered if aberrant Ca2+ signaling may 321 
underlie G85R-SOD1-YFP toxicity. To test this possibility, we performed ratiometric Ca2+ imaging using 322 
Fura-2, a fluorescent Ca2+ indicator dye, which was delivered to the presynaptic axon electrophoretically 323 
and allowed to diffuse into the “palm” and presynaptic branches (Fig.5A, regions of interest (ROIs) were 324 
selected to show 1: “palm”, 2-6: presynaptic axon which forms the giant synapse, and 7: another small 325 
presynaptic branch). In parallel, the presynaptic axon was subjected to basal stimulation while both pre- 326 
and post-synaptic membrane potentials were recorded. The presence of Fura-2 provides an indication of 327 
changes in Ca2+ levels and location during stimulation. To avoid interference with Ca2+ imaging, WT-328 
SOD1 and G85R-SOD1 constructs used in these studies lacked the YFP tag and injections were 329 
monitored by co-perfusion of Tetramethylrhodamine-dextran. While overall characteristics of synaptic 330 
function are similar with the introduction of Fura-2, the impairment of synaptic transmission by G85R-331 
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SOD1 was delayed in the presence of Fura-2 (>60 min vs. previously less than 30 min after G85R-SOD1 332 
injection), probably due to the buffering of Ca2+ by indicator dye. This impairment was correlated with a 333 
concurrent rise in Ca2+ levels at 60 min. Synapses injected with Fura-2 alone or Tetramethylrhodamine-334 
Dextran alone kept constant EPSP normally for >2hr as those injected with WT. Furthermore, synapses 335 
injected with WT-SOD1 behaved similarly as those with WT-SOD1-YFP, excluding the potential role of 336 
YFP tag on synaptic transmission. 337 
G85R-SOD1 infusion (n = 19) caused increases of Ca2+ throughout the presynaptic terminal 338 
compared with WT controls (n = 12), as derived from the ratios of (fluorescent intensity360nm)/(fluorescent 339 
intensity390nm) averaged across ROIs 2-6 (Fig.5B). While WT-SOD1 under basal stimulation showed no 340 
change in Ca2+ concentration after 1hr protein infusion (Fig.5C), G85R-SOD1 increased global Ca2+ 341 
concentration in the “palm”, the presynaptic giant axon (PreG), as well the other small presynaptic branch 342 
(PreS), with the most significant elevation at the site of G85R-SOD1 injection (Fig.5D) perhaps due to 343 
the highest G85R-SOD1 concentration on the injection site. Both the “palm” and PreS regions, further 344 
away from the injection site, would contain lower concentrations of mutant protein due to diffusion. 345 
Interestingly, the “palm” which lacks plasma membrane Ca2+ channels and doesn’t normally show Ca2+ 346 
increases during HFS did not exhibit increased Ca2+ with WT-SOD1 (Fig.5-1A), consistent with earlier 347 
findings (Smith et al. 1993). However, in the presence of G85R-SOD1, the “palm” also displayed 348 
aberrant Ca2+ increases with HFS (Fig.5-1B), suggesting that sources of Ca2+ other than plasma membrane 349 
Ca2+ channels may contribute to this Ca2+ misregulation. Taken together, the evidence suggests that G85R-350 
SOD1-induced Ca2+ influx may mediate its inhibitory effects on synaptic transmission and the effect may 351 
depend upon intracellular Ca2+ stores. 352 
Given that iHFS rescued G85R-SOD1-associated synaptic defects, we wondered if iHFS could 353 
correct the aberrant localization of Ca2+ increases. Fura-2 ratiometric Ca2+ imaging demonstrated Ca2+ 354 
increases during HFS in both WT- and G85R-SOD1-injected synapses (Fig.5-1), confirming previous 355 
findings of HFS on Ca2+ dynamics by others (Smith et al. 1993). In the presence of G85R-SOD1, Ca2+ 356 
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concentrations in the “palm” appeared more variable across the synapses, with some “palm” regions 357 
showing Ca2+ increases as high as those in the synaptic terminal, suggesting high baseline Ca2+ 358 
concentration. However, there seemed to be no significant difference between WT-SOD1 (n = 12) and 359 
G85R-SOD1 (n = 19) injected synapses at the injection site and the other locations within the presynaptic 360 
terminals during iHFS, indicating normal Ca2+ channel functions at the injection site, thereby excluding 361 
the possibility of physical membrane damage caused by the injection. Consistent with iHFS-rescue in 362 
synaptic physiology and in contrast to G85R-SOD1-induced Ca2+ influx in the absence of iHFS, aberrant 363 
Ca2+ activation was not observed after iHFS in G85R-SOD1-injected synapses (Fig.5E and F). These 364 
results suggest that iHFS may reset Ca2+ dynamics in the terminal and prevent the local Ca2+ overloads 365 
that contribute to synaptic dysfunction induced by G85R-SOD1.  366 
EGTA prevents toxic effects of G85R-SOD1-YFP on synaptic physiology and morphology   367 
The iHFS-rescue experiments in combination with Ca2+ imaging and the delayed inhibition produced 368 
by Fura-2 suggested that aberrant Ca2+ activation by G85R-SOD1 may be the cause of synaptic inhibition. 369 
To further test this hypothesis, we chelated free Ca2+ in the presynaptic terminal by co-injecting 50mM 370 
EGTA (final concentration at 5-10mM in the synapse). Previous studies had shown that EGTA levels less 371 
than 80mM do not affect synaptic transmission (Adler et al. 1991). EGTA was sufficient to block the 372 
inhibitory effects of G85R-SOD1-YFP on synaptic transmission and G85R-SOD1-YFP-injected synapses 373 
maintained steady EPSPs for over 2 hours without iHFS (n = 6), which was comparable to WT-SOD1-374 
YFP-injected synapses (Fig.6A and Fig. 6-1, 5 WT-SOD1- and 8 G85R-SOD1-infused synapses were 375 
also shown in Fig.1C). Not surprisingly, ratiometric Ca2+ imaging using Fura-2 did not show any local 376 
Ca2+ increases in synapses co-injected with G85R-SOD1 and EGTA (Fig.6B and C). Defects in synaptic 377 
vesicle pools, number and distribution induced by G85R-SOD1 were also corrected by EGTA, as 378 
evidenced by the usual RRP size, and normal mobilization rate (Fig.6D-E). Furthermore, EM showed 379 
comparable numbers of synaptic vesicles at the active zones (Fig.6F). The numbers of docked and 380 
electron lucent synaptic vesicles were similar between the WT-SOD1 and G85R-SOD1+EGTA-infused 381 
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synapses, while EGTA might slightly increase clathrin coating (Fig.6G, 102 synapses for each group). 382 
These results suggest that Ca2+ dysregulation may underlie G85R-SOD1-associated synaptic dysfunctions 383 
and that limiting increases in free cytoplasmic Ca2+ with EGTA may restore normal synaptic morphology 384 
and function. 385 
 386 
DISCUSSION 387 
The discovery of giant fibers in the squid nervous system by J.Z. Young (Young and Keynes 2005) 388 
more than 80 years ago led to several milestone discoveries in modern neuroscience, including the Nobel-389 
prize-winning work on ionic mechanisms for initiating and propagating action potentials by Andrew 390 
Huxley and Alan Hodgkin (Schwiening 2012). Although advanced imaging and genetic tools as well as 391 
new model systems have been developed in recent years, these classical mature synapse and axon models 392 
continue to be utilized to understand fundamental neurobiology and provide a unique model to study 393 
molecular mechanisms of human neurological diseases. For example, the original discovery of the 394 
molecular motor kinesin in isolated axoplasm from the squid led to studies of axonal trafficking deficits 395 
resulting from altered motor function in several neurodegenerative diseases (Song et al. 2016; Brady and 396 
Morfini 2017). In a similar way, studies of molecular mechanisms underlying basic synaptic physiology 397 
in the squid giant synapse have led to exploration of disease mechanisms involving synaptic dysfunction 398 
(Moreno et al. 2009). Here, we use the giant axo-axonic synapse in the squid stellate ganglion to study 399 
synaptic actions of mutant human SOD1 (G85R-SOD1) protein, which causes a familial form of 400 
Amyotrophic Lateral Sclerosis.   401 
Presynaptic injection of G85R SOD1 inhibits neurotransmission by disturbing synaptic vesicle 402 
physiology  403 
Synaptic loss at affected neuromuscular junctions leading to a dying-back neuropathy appears to be a 404 
primary defect associated with pathology in ALS patients and mouse models bearing G85R-SOD1 405 
mutations. Consistent with these observations,  we found that infusion of ALS-associated human G85R 406 
mutant SOD1 protein but not the wild-type SOD1 into the presynaptic terminal of the squid giant synapse 407 
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(SGS) significantly inhibited EPSPs, leading to a failure in eliciting postsynaptic action potentials. This 408 
occurred within 30min of continuous infusion into the presynaptic terminal without diminishing the 409 
presynaptic action potentials, while infusion of the WT-SOD1 had no effect on synaptic transmission as 410 
evidenced by sustained firing of synapses with constant EPSPs (Fig.1).  411 
 High frequency stimulus protocols designed to deplete the readily releasable pool (RRP) of 412 
presynaptic vesicles showed that vesicle dynamics were significantly inhibited by G85R-SOD1, reducing 413 
both the size of the RRP and the mobilization rate from the reserved pool (RP) to the RRP (Fig.2). This 414 
finding was further validated by EM data that demonstrated significant reductions of synaptic vesicles at 415 
active zones in the presence of G85R-SOD1 protein (Fig.3). Ultrastructural studies provided additional 416 
evidence of altered vesicle trafficking as membranous structures resembling multivesicular bodies and 417 
autophagosomes were identified in presynaptic regions infused with G85R-SOD1, but not WT-SOD1. 418 
Inhibition of synaptic transmission was reversed by stopping presynaptic infusion of G85R-SOD1 and 419 
allowing sufficient time for the protein to diffuse out of the synapse via the presynaptic giant axon (Fig.1-420 
2), which suggested that the synaptic machinery was not physically and permanently damaged.  421 
Nature of synaptic vesicle disturbance 422 
A clue to the mechanism for G85R-SOD1-induced synaptic inhibition came from an experiment 423 
where the synapse was exposed to intermittent HFS (iHFS) at 30min intervals before and during G85R-424 
SOD1 infusion. This was expected to inhibit synaptic transmission based on earlier results showing that 425 
continuous HFS depleted presynaptic RRP. Unexpectedly, G85R-SOD1-synapses exposed to iHFS 426 
maintained constant EPSPs for over 7 hours, exhibiting normal synaptic vesicle dynamics and normal 427 
numbers of synaptic vesicles at active zones despite the presence of pathogenic SOD1 protein (Fig.4). 428 
This finding led us to examine Ca2+ dynamics as HFS is known to redistribute Ca2+ both temporally and 429 
spatially (Smith et al. 1993).  430 
Live cell ratiometric Ca2+ imaging studies showed that G85R-SOD1 consistently increased Ca2+ 431 
levels in presynaptic terminals with the largest increases at the injection site, the site with highest G85R-432 
SOD1 concentration. Surprisingly, Ca2+ levels were also increased in the “palm” region, which lacks 433 
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plasmalemmal Ca2+ channels and normally does not exhibit Ca2+ increases in response to HFS (Fig.5). 434 
These data suggested that the source of Ca2+ may not be restricted to or dependent on local plasma 435 
membrane Ca2+ channels. This agrees with previous findings that Ca2+ influx solely through voltage-gated 436 
Ca2+ channels is not able to induce motor neuron death (Van den Bosch et al. 2002). Instead, release of 437 
Ca2+ from endoplasmic reticulum and/or mitochondrial stores is required, and these organelles may 438 
release Ca2+ in response to misfolded G85R-SOD1 protein.  439 
Co-injection of EGTA and application of iHFS prevent physiopathology 440 
If increased free Ca2+ levels are responsible for synaptic failure, co-injection of EGTA, a Ca2+ 441 
chelator, at levels that do not affect synaptic transmission at the squid giant synapse should prevent 442 
synaptic inhibition by G85R-SOD1 by buffering free Ca2+. Consistent with the conclusion that 443 
presynaptic increases in free Ca2+ levels were responsible for the observed synaptic dysfunction, EGTA 444 
prevented inhibition of synaptic transmission when co-injected into the presynaptic terminal with G85R-445 
SOD1, as documented by 1) EPSPs remained constant for over 2 hours; 2) sufficient numbers of synaptic 446 
vesicle were present at the active zones with normal mobilization from RP to RRP; and 3) cytoplasmic 447 
free Ca2+ levels did not increase (Fig.6). Similar effects were also achieved by iHFS applied every 30min 448 
for over 7 hours (Fig.4). Interestingly, iHFS also abolished the Ca2+  increases induced by G85R-SOD1 449 
(Fig.5) perhaps by redistributing Ca2+ and restoring homeostasis. This process may alter regulation of 450 
other organelles such as ER, mitochondria, and autophagosomes in the synapse to restore overall synaptic 451 
health. However, determining the exact molecular mechanisms requires more in-depth studies.  452 
Questions remain as to how increased cytoplasmic free Ca2+ alters synaptic vesicle dynamics in the 453 
presynaptic terminal. Ca2+ is a key player in many cellular and subcellular processes, is required for 454 
regular synaptic function, and is normally tightly regulated. In normal synapses,  free Ca2+ increases are 455 
largely restricted to the active zone through local plasmalemmal channels during synaptic transmission 456 
(Sudhof 2004). The levels of EGTA used in these studies do not affect Ca2+ influx at active zones but do 457 
buffer cytoplasmic free Ca2+. There are multiple Ca2+ sensors with a wide range of affinities in the 458 
presynaptic compartment, all of which may contribute to one or more of the complex steps involved in 459 
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synaptic transmission and synaptic vesicle dynamics. While the role of some of these sensors is 460 
established, such as evidence that synaptotagmin is the Ca2+ sensor for synaptic vesicle fusion and 461 
neurotransmitter fast release, the physiological roles for many others remain unclear (Sudhof 2004).  462 
The existing literature has suggested  a variety of potential mechanisms for Ca2+ related pathology in 463 
both human and mouse ALS-vulnerable neurons (Grosskreutz, Van Den Bosch, and Keller 2010), such as 464 
the subgroups of motor neurons in spinal cord and brainstem expressing low levels of Ca2+ buffering 465 
proteins, even at the presymptomatic stages. Similarly, Ca2+ dysregulation has also been observed in 466 
several other neurodegenerative diseases and may lead to Unfolded Protein Responses (UPR) and ER-467 
stress-related signaling activation (Remondelli and Renna 2017; Walker and Atkin 2011; Hetz and 468 
Saxena 2017; Grosskreutz, Van Den Bosch, and Keller 2010), Ca2+ permeable AMPA receptor 469 
dysregulation (Tortarolo et al. 2006; Tateno et al. 2004; Van Den Bosch et al. 2006), ER/mitochondria 470 
membrane collapse (Watanabe et al. 2016; Bernard-Marissal, Chrast, and Schneider 2018; Tortarolo et al. 471 
2006), and aberrant Ca2+ influx in affected neurons and glia. In addition, changes in protein expression in 472 
affected motor neurons (e.g. Ca2+ channels and regulators) may also contribute to dysregulation of Ca2+ 473 
levels in disease. While altered transcription may play a role in the slow progression of the disease, this is 474 
unlikely to contribute here given the time scale and reversibility of these effects as well as the lack of 475 
strong evidence of local transcription in the squid giant synapse.  476 
In conclusion, our results in the SGS indicate that mutant SOD1 affects the regulation of free Ca2+ 477 
levels in the presynaptic terminal, leading to a disruption of normal vesicle trafficking. These effects were 478 
not restricted to regions near the active zones but were more extensive and affected regions of the 479 
presynaptic compartment that lack plasmalemmal Ca2+ channels. The effects of mutant SOD1 may occur 480 
without affecting the activity of local plasmalemmal Ca2+ channels required for neurotransmitter release 481 
at the active zone, given that 1) presynaptic regions lacking Ca2+ channels also showed increased levels of 482 
free Ca2+, 2) low levels of EGTA can reduce free Ca2+ levels in the presence of G85R-SOD1 without 483 
affecting Ca2+ influx through plasmalemmal Ca2+ channels responsible for normal synaptic transmission, 484 
and 3) the discovery that iHFS could rescue synaptic transmission. The effect of iHFS was unexpected 485 
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and further argues for normal function of active zone Ca2+ channels in the plasmalemma independent of 486 
intracellular stores of Ca2+.  The effect of iHFS suggests that further study is needed of how patterns of 487 
activity can preserve synaptic function and this may be a basis for novel therapeutic interventions in ALS.  488 
The effects observed here may relate to those observed earlier in the squid giant axon innervating 489 
muscles in the mantle. There we found that G85R-SOD1-YFP inhibited axonal trafficking of presynaptic 490 
vesicles by activating a MAPK stress pathway, which impaired kinesin-based transport responsible for 491 
anterograde cargo transport (Song et al. 2013). In addition, we observed that that G85R-SOD1 was 492 
associated with several synaptic proteins critical for synaptic transmission, such as Synapsin and 493 
Syntaxin-binding protein 5, at a much higher level than WT-SOD1-YFP. HSP110, an HSC70 Co-494 
Chaperone which prevented the neurotoxicity of G85R-SOD1 in the axon by potentially sequestering or 495 
refolding G85R-SOD1, also abolished the association of Synapse-associated protein and Syntaxin-496 
binding protein 5 with G85R-SOD1-YFP (Song et al. 2013). The roles that G85R-SOD1 interactions with 497 
synaptic proteins may play in affecting synaptic vesicle dynamics as well as regulation of these 498 
interactions via Ca2+ dependent or independent pathways remain to be determined. Various 499 
neuropathogenic changes have been proposed to be a consequence of Ca2+ dysregulation, such as UPR 500 
and autophagy, in ALS and several other neurodegenerative diseases. Our EM data (Fig.6) showed that 501 
EGTA, when co-injected with G85R-SDO1, restored synaptic morphology and prevented the formation 502 
of pre-autophagosome and adjoining pre-lysosomes, which were observed when presynaptic G85R-SOD1 503 
was injected alone.  504 
Implication of acute toxic effects of G85R-SOD1 on squid giant synapse physiology as relates to 505 
longer term ALS pathology in mammalian synapses 506 
Like many other adult-onset neurodegenerative diseases, one big puzzle in the field is “why does it 507 
take 40-50 years to develop ALS?”. Several disease-related processes occur during aging which can be 508 
overcome in young neurons due to robust compensatory mechanisms. In this study, we focus on acute 509 
effects of pathogenic SOD1, but a number of age-related factors may explain the delayed onset of clinical 510 
symptoms.   511 
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Unlike the acute injection of pathogenic SOD1 in this study where we observed the presence of pre-512 
autophagosome and pre-lysosome formation within the time frame of both electrophysiological 513 
recordings and morphological studies, ALS-associated mutant SOD1 in patients misfolds and 514 
accumulates gradually to pathological levels over time, allowing adaptive changes in cellular and 515 
molecular mechanisms underlying synaptic transmission. This is due to, at least partially, mechanisms for 516 
actively removing pathogenic proteins in early stages of disease, which may be sufficient to slow the 517 
accumulation of toxic materials. However, these clearance mechanisms may eventually be unable to keep 518 
up with misfolded protein accumulations.  By directly injecting defined levels of mutant SOD1 into an 519 
isolated squid giant synapse system, we ensured accumulation of misfolded protein locally in the 520 
synapses within a short period of time which limits compensatory effects in the isolated synapse with 521 
little protein degradation and synthesis in this time frame.  522 
Similar to robust protein homeostatic pathways during development and maturation, Ca2+ buffering 523 
mechanisms and synaptic transmission may be redundant early on in the complex system such as the 524 
mammalian models where neuronal circuits (including the other cell types) are intact and dynamic. They 525 
can adapt to slowly increased stresses created by the presence of mutant SOD1, much as synaptic 526 
functions exhibit adaptive changes during normal aging. The use of isolated acute preparations of giant 527 
synapse also eliminates the possibility that transcriptional changes of synaptic proteins can compensate 528 
for the effects of toxic proteins on synaptic transmission machinery.  For example, the question of 529 
whether ALS-affected neurons show hyper- or hypo- excitability has been debated for some time. As a 530 
matter of fact, several groups have reported hyperexcitability of motor neurons at early stages followed by 531 
hypoexcitability at later stages of ALS in both iPSC culture models and in mouse models. These changes 532 
may be due to various compensatory mechanisms at the molecular, cellular and systemic levels which 533 
also may contribute to the delayed onset of symptoms. Here, we can isolate inhibitory effects due to the 534 
simplicity of the squid synapse model system where many other factors, such as compensation from other 535 
neurons, changes in gene expression or axonal transport, or the impact of a complex environment can no 536 
longer play a role.  537 
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Furthermore, it is worth keeping in mind that synaptic loss, as a result of gradual decrease in synaptic 538 
strength as demonstrated here, occurs long before cell death and can be observed in presymptomatic 539 
stages of both ALS mice and patients. By measuring EPSP slopes and vesicle dynamics in the squid giant 540 
synapse, we have provided a sensitive readout of neurotransmission in real time and revealed changes in 541 
synaptic strength which are more subtle in pre-symptomatic patients and mouse models but are detectable 542 
long before clinically relevant behavioral abnormalities appear. Correlating Ca2+ dynamics and HFS 543 
effects with synaptic health in real time illuminates the kinetic changes in the presynaptic terminal with 544 
high temporal and spatial resolution, which suggests the importance of identifying potential therapeutic 545 
time windows. The acute effects demonstrated here may illustrate molecular mechanisms underlying 546 
disease pathology that are manifested over time in patients.  547 
Relevant to mammalian physiology and pathology, the squid giant synapse also shares fundamental 548 
synaptic machineries with neuromuscular junctions in human, making it a unique ALS-disease model 549 
with a potential for answering important but otherwise difficult questions about pathogenic mechanisms 550 
and synaptic transmission in motor neuron diseases.  The squid giant synapse provides a unique platform 551 
for 1) performing live measurements of both pre- and post- synaptic activities in response to disease-552 
associated proteins with temporal and spatial resolutions surpassing those in most other model systems; 2) 553 
conducting morphological studies in the same preparations characterized by live-imaging of cellular and 554 
molecular pathways, electrophysiological studies and electron microscopy in the same sample; 3) 555 
evaluating pharmacological inhibitors, biochemical tools, and electrophysiological protocols that may 556 
rescue disease phenotypes in a time dependent manner; and 4) identifying translatable mechanistic 557 
findings, due to the highly conserved synaptic machinery, that will provide better understanding and 558 
treatment of multiple neurodegenerative diseases where misfolded proteins cause disease pathology.  559 
In conclusion, the development of novel models for study of neurodegenerative diseases such as 560 
those using the squid nervous system has the potential to provide unique insights into disease 561 
mechanisms.  For example, the combination of our electrophysiological studies in the giant synapse with 562 
studies of axonal transport in isolated axoplasm from the postsynaptic giant axon of the squid, allowed us 563 
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to identify signaling pathways altered by these pathogenic proteins (Song et al. 2013). These results were 564 
then developed further in mouse models of ALS and patient tissues or iPSCs. Our results here are also 565 
consistent with previous findings of Ca2+ dysregulation and synaptic dysfunction in both ALS mice and 566 
patient derived neurons (Tradewell et al. 2011; Grosskreutz, Van Den Bosch, and Keller 2010; Leal and 567 
Gomes 2015). For example, affected neurons exhibit aberrant Ca2+ dynamics, which leads to 568 
hyperexcitability or hypoexcitability at various stages (Wainger et al. 2014; Devlin et al. 2015; Martinez-569 
Silva et al. 2018). Further, oculomotor neurons, which are relatively spared in ALS, have a higher 570 
buffering capacity for Ca2+ (Vanselow and Keller 2000; Obal, Engelhardt, and Siklos 2006), which was 571 
thought to contribute to their overall resistance to pathology in patients and mouse models. Those data 572 
were unclear, however, as to whether these changes involved plasmalemmal Ca2+ channels or intracellular 573 
Ca2+ stores or both, an issue that could be addressed in the SGS.  574 
Given recent work on the squid genome and improved mariculture protocols that have the potential 575 
to allow systematic long-term studies of squid nervous systems, there will be opportunities to develop 576 
novel transgenic ALS squid models. Therefore, studies using the squid giant synapse will continue to 577 
complement studies using human iPSCs and animal models of ALS as we seek to understand how 578 
multiple disease related pathways can independently affect the pleiotropic neuronal functions that interact 579 
to produce the phenotype of ALS, a multifactorial disease with a complex disease pathology.  580 
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LEGENDS 733 
Figure 1. Presynaptic infusion of G85R-SOD1-YFP inhibited synaptic transmission. (A) Diagram of 734 
experimental setup. Presynaptic 2nd order giant axon branch (black) and postsynaptic 3rd order giant axon 735 
(red) form the giant synapse in the stellate ganglion. Two electrodes were inserted in the presynaptic 736 
axon, one at the “palm” to deliver electronic stimulation at 0.03 Hz (each pulse is 2μA for 2ms) and the 737 
other in the presynaptic terminal for recording presynaptic potentials as well as injecting 50μM SOD1 738 
proteins and reagents of interest at 0.1 Hz, each injection was 50 psi for 250 ms. The 3rd electrode was 739 
inserted in the postsynaptic axon to record postsynaptic potentials. (B) Under current clamping condition, 740 
G85R-SOD1-YFP injected synapses showed reductions in postsynaptic potential (Vpost) within 30min and 741 
a failure to elicit a postsynaptic action potential in 40min, compared with the control before injection. (C) 742 
EPSP slopes of WT-SOD1-YFP injected-synapses (n = 5) and G85R-SOD1-YFP-injected synapses (n = 743 
8) were normalized to the initial time point (-30min), 30min before the beginning of SOD1 injections. 744 
Averaged EPSP slopes were plotted with error bars showing standard error. The thick black bar indicates 745 
the duration of SOD1 infusion starting at time 0. G85R-SOD1-YFP consistently inhibited synaptic 746 
transmission as shown by reductions in the EPSP slope, while WT-SOD1-YFP infusions showed no 747 
effect on EPSPs. Control synapses infused with fluorescent dextran showed normal firing similar to the 748 
WT-SOD1-YFP infused synapses (Fig.1-1). Moreover, synaptic function gradually recovered in G85R-749 
SOD1-YFP-infused synapses after protein infusion was stopped, excluding the possibility of physical 750 
damage of synaptic machinery due to injection (Fig.1-2).  751 
 752 
Figure 2. Presynaptic infusion of G85R-SOD1-YFP altered synaptic vesicle dynamics. (A) Series of 753 
six continuous trains of High frequency stimulation (HFS, each train is 50 Hz for 5 seconds with 5 754 
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seconds between trains) was applied to the synapses infused with SOD1 proteins for 15min prior to HFS 755 
trains. WT-SOD1-GFP-injected synapses showed constant EPSP slope at the beginning of each train 756 
suggesting robust neurotransmission (>200, also see Fig.2-1 for the 6th train). However, G85R-SOD1-757 
YFP-injected synapse started to show reductions in synaptic transmission, as evidenced by the dramatic 758 
decrease in EPSP slopes taken during the 1st train both at the beginning and at the steady state, suggesting 759 
severe depletion of synaptic vesicles from both the readily releasable pools and the reserved pools. This 760 
inhibition was more obvious in the 6th train (Fig.2-1) (B) EPSPs of the 1st train from WT-SOD1-YFP-761 
injected synapses (black, n = 11) and from G85R-SOD1-YFP-injected synapses (red, n = 6) were 762 
integrated and averaged, followed by linear fit. The intersection with Y axis indicated the size of the 763 
readily releasable vesicle pool (RRP) and the slope indicated the mobilization rate of vesicles from the 764 
reserved pool (RP) to RRP. (C) Normalized to baseline values before the injection of SOD1-YFP, RRP 765 
size and mobilization rate from the 1st train were plotted as individual biological replicates (n = 11 for 766 
WT-SOD1-infused synapses and n= 6 for G85R-SOD1-infused synapses) to show significant reductions 767 
in both RRP and mobilization of vesicles from the RP by G85R-SOD1-YFP, but not by WT-SOD1-YFP.  768 
 769 
Figure 3. Presynaptic infusion of G85R-SOD1 inhibited synaptic vesicle availability. Representative 770 
electron microscopy images illustrate morphology of active zones (AZs, labeled with red *) and numbers 771 
of synaptic vesicles (SVs) in fixed synapses infused with WT-SOD1 (A, n = 3) and G85R-SOD1 (B, n = 772 
3). G85R-SOD1-infused synapses showed vacant active zones and occasional abnormal membranous 773 
structures (indicated by blue # and purple ^). (C-F) Quantification of averaged vesicle number across all 774 
AZs from 102 WT- and 102 G85R-SOD1-YFP-infused synapses showed statistically significant 775 
reductions in the total vesicle number and in the electron lucid vesicle number by G85R-SOD1-YFP as 776 
compared to WT-SOD1. The clathrin coated vesicles and the large electron lucid vesicles were 777 
comparable between WT and G85R-SOD1-YFP infused synapses. Nested one-way ANOVA was 778 
performed to compare WT and G85R infused synapses (P<0.0001) as well as across biological triplicates 779 
within each group (P>0.05). (G) Averaged number of SVs per AZ were plotted along the distance from 780 
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AZ (binned by 50nm). (H) Distance distribution plot of SVs in each 50μm bin showed a global reduction 781 
of SVs from G85R-SOD1-YFP infused synapses regardless of the distance from the AZs. Due to the 782 
drastically reduced numbers of SVs far (>675nm) from the AZs in both WT and G85R synapses, the 783 
reduction seemed to disappear or even be reversed, however, the differences far from the AZ may not be 784 
significant due to the substantially decreased numbers of vesicles in that area for both WT and G85R 785 
synapses. (I) Cumulative SV distribution plots showed similar distribution patterns of vesicles in WT 786 
(solid line) and G85R (dashed line) synapses, confirming the even inhibition of SV availability by G85R-787 
SOD1 independent of the distance from the AZs.   788 
 789 
Figure 4. Intermittent HFS (iHFS) prevented synaptic transmission deficits caused by G85R-SOD1-790 
YFP. (A) iHFS (5 sec of 50 Hz applied every 30 min) was first applied to the synapse at time 0 before 791 
G85R injection, both pre- and post-synaptic membrane potentials were recorded 1min after HFS (P1). (B) 792 
If iHFS trains were applied every 30min before and during continuous SOD1-YFP infusion into the 793 
synapse, G85R-SOD1 no longer inhibited synaptic transmission and the synapse continued to fire even 794 
after 7 hours without significant changes in either pre- or post- synaptic potentials (P15) (C) EPSP slopes 795 
remained constant and comparable under basal stimulation with iHFS in WT and G85R-synapses. (D) 796 
EPSP slope from one single train of iHFS showed no significant difference between WT- and G85R- 797 
synapses except for occasional augmentation seen in G85R-SOD1-YFP-infused synapses. (E) To evaluate 798 
the vesicle dynamics, EPSP slopes were measured and integrated during HFS trains applied either with 799 
2hr WT- or G85R-SOD1-YFP infusion in the presence of iHFS every 30 min (n = 6). There were no 800 
significant differences in RRP size and mobilization rate of vesicles trafficking from RP to RRP by 801 
G85R-SOD1-YFP. (F) EM showed normal presynaptic structure with normal numbers of vesicles at the 802 
active zone in G85R-SOD1-YFP-infused synapses when iHFS was applied. Interestingly, in 3 out of 5 803 
synapses, HFS restored firing in G85R-SOD1-YFP-infused synapses, where EPSPs were significantly 804 
inhibited (Fig.4-1).  805 
 806 
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Figure 5. Presynaptic infusion of G85R-SOD1-His increased Ca2+ levels in the presynaptic terminal. 807 
Ratiometric live Ca2+ imaging was performed every 30sec after electrophoretic (100 nA current) infusion 808 
of a Ca2+ indicator, 1mM Fura-2 in 100mM KCl, into the presynaptic axon through the 1st presynaptic 809 
stimulation electrode inserted into the “palm” (Fig.1A).  Fura-2 injection continued for 10min and the 810 
synapse was allowed to equilibrate for 30 min before SOD1 injection through the 2nd electrode to ensure 811 
Fura-2 was diffused evenly throughout the whole presynaptic terminal at roughly 100μM. Ratiometric 812 
images were taken at Ex360 nm and Ex390 nm assisted by ultra-high-speed wavelength switching 813 
Lambda DG-4/5 xenon arc lamp system. Ratios at various locations (A) were calculated as (fluorescent 814 
intensity360nm)/(fluorescent intensity390nm) to provide a measure of intracellular Ca2+ concentrations. The 815 
blue arrow indicates the injection site for SOD1 proteins. 1: “Palm”, 2-6: PreG, 4: Infusion site, 7: PreS. 816 
(B) G85R-SOD1-His induced Ca2+ increases while WT-SOD1-His had no effect on Ca2+ concentration. 817 
Raw Ca2+ concentrations were derived from the equation [Ca2+] = Kdc (R− Rmin)/(Rmax − R) and 818 
averaged across 12 WT- and 19 G85R-SOD1-injected presynaptic terminals (PreG) respectively. Kdc, 819 
Rmin and Rmax were calculated from standards as described in methods. Though different synapses 820 
varied in their baseline Ca2+ concentrations, G85R consistently increased [Ca2+] at around 60 min after 821 
protein injection whereas WT had no effect. (C-D) Baseline normalized Ca2+ ratio defined as (R120-R0)/R0 822 
(R120: 60min after SOD1 injection, R0: before SOD1 injection) were plotted at 4 sites for WT (n=12) and 823 
G85R (n=19). G85R-SOD1 caused increases in [Ca2+] at all sites including the “palm” where Ca2+ 824 
channels are sparse or absent. The increase in [Ca2+] correlated roughly with G85R-SOD1 concentration, 825 
with the highest levels at the injection site and lowest in PreS, a smaller presynaptic axonal branch 826 
infused with fura-2 at a comparable concentration but with a lower SOD1 concentration due to slower 827 
diffusion from the injection site in PreG. (E-F) iHFS applied at 30 min after SOD1 injection seemed to 828 
restore Ca2+ homeostasis in G85R-SOD1-injected synapses (n = 19) and this equilibrium lasted at least 2 829 
hours after iHFS, similar to that in WT (n = 12), this suggested the possibility that redistribution of Ca2+ 830 
is induced by iHFS. As expected, Ca2+ levels increased during HFS in synapses infused with either WT or 831 
G85R-SOD1 proteins (Fig. 5-1). 832 
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 833 
Figure 6. EGTA, a Ca2+ chelator, prevented G85R-SOD1-YFP-induced synaptic dysfunctions. (A) 834 
EPSP slopes of 6 double injected synapses (50mM EGTA and 50μM G85R-SOD1-YFP) were plotted 835 
from 30 min before the injection to 2 hours after the injection. There was no reduction in EPSP slopes 836 
with EGTA and G85R-SOD1-YFP in contrast to that seen in synapses injected with G85R-SOD1-YFP 837 
alone (n = 8) or WT-SOD1-YFP alone (n = 5), data for G85R- and WT-SOD1 from Figure 1C is 838 
included for comparison. All EPSP slopes were averaged and plotted with error bars indicating standard 839 
error (for unnormalized data, see Fig. 6-1). (B) Ratiometric Fura-2 Ca2+ imaging showed comparisons of 840 
Ca2+ concentrations in the presynaptic terminals (PreG) injected with WT-SOD1, G85R-SOD1, and 841 
G85R-SOD1+ EGTA, EGTA prevented the Ca2+ increase caused by G85R-SOD1 (n = 4). Due to the 842 
chelating effect of EGTA, the basal level of Ca2+ decreased over time during co-infusion of G85R and 843 
EGTA. (C) Normalized ratios (subtracting levels with EGTA alone), positively correlated with Ca2+ 844 
concentrations, showed constant basal Ca2+ levels at various presynaptic regions injected with G85R-845 
SOD1 in the presence of EGTA. (D) EPSP slopes from synapses injected with EGTA and G85R-SOD1 846 
were integrated, normalized to the initial time point before the injection, and fit linearly to show RRP size 847 
as indicated by the intersection with the Y axis and the vesicle mobilization rate from RP to RRP as 848 
indicated by the slope of the linear fit. Compared with WT-SOD1-injected synapses (green) and synapses 849 
before injections (black), EGTA+G85R-SOD1-injected synapses showed little change in the RRP size 850 
and the mobilization 120 min after injection (red) and 180 min after injection (blue). (E) Quantification of 851 
RRP size and mobilization for synapses injected with WT-SOD1 (n = 11), or G85R-SOD1 (n = 6), or 852 
G85R-SOD1 + EGTA (n = 5) showed that EGTA prevented the decreases in RRP size and mobilization 853 
rate caused by G85R-SOD1-YFP. Error bars indicate standard error. (F) Representative EM image 854 
showed abundant synaptic vesicles at the active zone of a synapse injected with EGTA and G85R-SOD1-855 
YFP. (G) EGTA restored the synaptic vesicle numbers to normal at the active zones (102 active zones 856 
from 3 independent experiments for each group).   857 
 858 
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EXTENDED DATA 859 
Figure 1-1. No effects of fluorescent dextran on synaptic transmission. Synapses infused with 860 
rhodamine-dextran alone kept firing for >2hr, without significant changes in synaptic strength as 861 
evidenced by constant postsynaptic membrane potential waveform (A) and EPSP slope (B). 862 
 863 
Figure 1-2. Recovery of synaptic transmission after the removal of G85R-SOD1-YFP. The synapse 864 
was injected with G85R-SOD1-YFP continuously for 30 min till the significant reduction in EPSP slope 865 
and the failure to elicit a postsynaptic action potential. As the injection stopped, G85R-SOD1-YFP slowly 866 
diffused away from the presynaptic terminal to the axon, leading to a full recovery of EPSP after 150 min, 867 
suggesting that synaptic machinery remained intact after treatment. After the synapse and 868 
neurotransmission were stabilized for more than 1 hour, G85R-SOD1-YFP was injected again and a 869 
similar inhibitory effect was observed. 870 
 871 
Figure 2-1. Significant inhibition of EPSP by continuous HFS in G85R-SOD1-YFP-infused synapse. 872 
EPSP slopes taken during the 6th train in a set of continuous trains of HFS showed even more dramatic 873 
decreases by G85R-SOD1-YFP, compared with the WT-SOD1-YFP, particularly at the beginning, 874 
suggesting limited synaptic vesicle availability, consistent with the morphological changes found in EM. 875 
Note that in panel 2A, the EPSP slope with G85R-SOD1-YFP in the 1st  train was initially >150, while in 876 
the 6th train, it never got above 40.  In contrast, the initial EPSP slopes in the 1st train and the 6th train were 877 
almost identical after perfusion with WT-SOD1-YFP. 878 
 879 
Figure 4-1. Rescuing effects of HFS in dying synapses. In 3 out of 5 synapses where the EPSP slopes 880 
were significant inhibited by G85R-SOD1-YFP but were still above 50, one train of HFS surprisingly 881 
restored neurotransmission as indicated by the rescue of EPSP slope. Synaptic membrane potentials were 882 
measured in pre- and post-synaptic terminals before G85R-SOD1 infusion (A), after inhibition (B), and 883 
after one train of HFS (C). HFS partially restored the RRP size without rescuing vesicle mobilization rate 884 
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in these synapses. In the other 2 synapses where EPSP slopes had dropped below 50, a train of HFS 885 
further decreased the EPSP slope to almost 0, consistent with its role in depleting RRP.  886 
 887 
Figure 5-1. Increases in Ca2+ levels under HFS. Synapses infused with WT-SOD1 (A) of G85R-SOD1 888 
(B) exhibited increased Ca2+ levels upon HFS, mainly in the presynaptic terminals, with comparable 889 
changes at the protein infusion site and the rest of the terminal (PreG). The “Palm”, which lacks Ca2+ 890 
channels didn’t show changes in Ca2+ influx, consistent with previous findings. G85R-SOD1 didn’t seem 891 
to alter the overall pattern, except for larger fluctuations particularly at the “Palm” and the protein 892 
infusion site, which may indicate changes in Ca2+ homeostasis independent of Ca2+ channels.  893 
 894 
Figure 6-1. Unnormalized EPSP slopes. EPSP slopes were measured and plotted without normalization 895 
for synapses infused with WT-SOD1-YFP (A), G85R-SOD1-YFP (B), and G85R-SOD1-YFP + EGTA 896 
(C) 897 
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